Quantcast

Latest Ketorolac Stories

2014-09-08 08:29:52

MISSISSAUGA, ON, Sept. 8, 2014 /PRNewswire/ - Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that it has reached a full settlement with Mallinckrodt Inc. of Nuvo's claims and Mallinckrodt's counterclaim relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid(®) and Pennsaid 2% in the United States. Under the terms of the settlement agreement, Mallinckrodt will return...

2014-09-03 08:33:15

Sweden is latest country to grant marketing authorization ATLANTA, Sept. 3, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Swedish Medical Products Agency has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME)...

2014-08-11 16:28:03

-- FDA Approval of Omidria(TM) Received on May 30, 2014 - SEATTLE, Aug. 11, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced financial results and highlights for the second quarter of 2014, which include: -- 2Q...

2014-08-08 08:25:41

SEATTLE, Aug. 8, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference in New York next week. The presentation is scheduled for Tuesday,...

2014-06-25 08:30:55

GREENWOOD VILLAGE, Colo., June 25, 2014 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has informed the Transplant and Ophthalmology Division of the FDA of its intent to reduce the patient sample size in the OptimEyes Study for the treatment of Diabetic Macular Edema (oral treatment with Optina(TM)). This trial was intended to enroll 450 patients and was powered at 95%. The present enrollment of over 355 patients provides an adequate power of 88%,...

2014-06-24 08:32:41

MENLO PARK, Calif., June 24, 2014 /PRNewswire/ -- ForSight VISION5 is pleased to announce that Charles Semba, MD has joined the company as Chief Medical Officer from Shire Pharmaceuticals where he served as Vice President, Clinical Medicine (Ophthalmology). ForSight VISION5 is developing non-invasive drug delivery products to replace eye drops and provide sustained therapy for major anterior segment eye diseases including glaucoma, dry eye, and allergy....

2014-06-23 08:27:39

ATLANTA, June 23, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Italian Medicines Agency (Agenzia Italiana del Farmaco) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to...

2014-06-18 12:37:20

LONDON, June 18, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2014-2024http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharma_leader_series_top_25_ophthalmic_drug_manufacturers_2014_2024.html Report DetailsNew study shows you commercial prospects for leading eye drug producersWhat does the future hold for top companies in the pharma ophthalmics industry? Visiongain's brand new report...

2014-06-02 08:29:17

-- Omeros to Host Conference Call Today at 4:30 p.m. ET -- SEATTLE, June 2, 2014 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved Omidria(TM) (phenylephrine and ketorolac injection) 1%/0.3% for use during cataract surgery or intraocular lens replacement (ILR) to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative pain. The approval comes with no...

2014-05-15 12:35:20

LONDON, May 15, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Ophthalmic Drugs: World Market Prospects 2013-2023http://www.reportbuyer.com/pharma_healthcare/treatments/eye_care/ophthalmic_drugs_world_market_prospects.html Report DetailsHow to find trends and revenue predictions for the ophthalmic drug industryWhat are the commercial prospects for treating eye disorders? Visiongain's new report gives you forecasted revenues to 2023. It explains trends,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related